Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers

Shots:

• Navrogen expands its collaboration with Levena to develop ADCs targeting humoral immuno-suppressed cancers
• The collaboration will deploy Levena’s linker and cytotoxic payload chemistry expertise with Navrogen’s cancer-targeting Abs discovered utilizing HIO platform technologies. Levena will also utilize its process development and GMP capabilities
• The expansion of collaboration allows Navrogen to advance ADCs toward clinical studies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire